» Articles » PMID: 31243520

Early Central Vs. Peripheral Immunological and Neurobiological Effects of Fingolimod-a Longitudinal Study

Overview
Specialty General Medicine
Date 2019 Jun 28
PMID 31243520
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Fingolimod (FTY) is known to have multiple effects on the immune system and the central nervous system (CNS) in patients with multiple sclerosis (MS). In this study, we evaluated the immunological and neurobiological effects of FTY in MS. Blood and cerebrospinal fluid (CSF) samples were collected from 15 MS patients before first FTY administration and after 4 months of FTY therapy. Immunophenotyping and evaluation of sphingosine-1-phosphate (S1P), neurofilament light chain (NFL), S-100 and neuron-specific enolase (NSE) levels were conducted. After 4 months of FTY therapy, absolute cell count in CSF was decreased from 6.33 to 2.43 MPt/l, accompanied by decreases of CD3+ (2.22 to 0.65 MPt/l) and of CD4+ counts (1.60 to 0.39 MPt/l). In blood, CD3+ (1.05 to 0.09 GPt/l), CD4+ (0.80 to 0.02 GPt/l), CD8+ (0.23 to 0.04 GPt/l) and CD19+ (0.21 to 0.01GPt/l) cell counts were as well reduced. CD14+ cell count remained stable over the same period (0.24 to 0.26GPt/l). NFL and S1P levels in CSF and blood were reduced over time (NFL: CSF 1759 to 1359 pg/l, blood 8.42 to 7.36 pg/l; S1P: CSF 2.12 to 0.71 nmol/l, blood 392.1 to 312.9 nmol/l). Strong correlations between CSF and blood NFL levels were observed. Neuronal damage markers such as S-100 (1.86 to 1.69 μg/l) and NSE (9.53 to 8.67 μg/l) were reduced to a lesser degree than other markers. FTY exerted significant effects on immunological and neurobiological markers in the central and peripheral compartment. Decreases in levels of neuroinflammatory and neurodegenerative markers were already evident after 4 months of treatment. Four-month serum NFL level appears to be a useful marker for FTY efficacy that correlates well with changes in the CNS compartment. KEY MESSAGES: FTY has important immunological effects in both central and peripheral compartments. Cellular effects of FTY effects are more pronounced in the blood than in the CSF. FTY reduces S1P and NFL levels in CSF and serum. Serum NFL appears to be a useful marker for FTY therapy.

Citing Articles

Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis.

Constantinescu V, Haase R, Akgun K, Ziemssen T Front Pharmacol. 2024; 15:1431380.

PMID: 39364051 PMC: 11447318. DOI: 10.3389/fphar.2024.1431380.


S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review.

Constantinescu V, Haase R, Akgun K, Ziemssen T Ther Adv Neurol Disord. 2022; 15:17562864221133163.

PMID: 36437849 PMC: 9685213. DOI: 10.1177/17562864221133163.


Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Biernacki T, Kokas Z, Sandi D, Fuvesi J, Fricska-Nagy Z, Farago P Int J Mol Sci. 2022; 23(6).

PMID: 35328802 PMC: 8951485. DOI: 10.3390/ijms23063383.


Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.

Harris S, Comi G, Cree B, Arnold D, Steinman L, Sheffield J Eur J Neurol. 2021; 28(11):3722-3730.

PMID: 34292643 PMC: 9291872. DOI: 10.1111/ene.15009.


Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis.

Alagaratnam J, Von Widekind S, De Francesco D, Underwood J, Edison P, Winston A BMJ Neurol Open. 2021; 3(1):e000143.

PMID: 34223154 PMC: 8211066. DOI: 10.1136/bmjno-2021-000143.


References
1.
Yoo H, Lee E, Lee W, Lee Y . Simultaneous quantitative analysis of sphingoid base 1-phosphates in biological samples by o-phthalaldehyde precolumn derivatization after dephosphorylation with alkaline phosphatase. Anal Biochem. 2002; 303(2):167-75. DOI: 10.1006/abio.2002.5579. View

2.
Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C . FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008; 71(16):1261-7. DOI: 10.1212/01.wnl.0000327609.57688.ea. View

3.
Chun J, Hartung H . Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010; 33(2):91-101. PMC: 2859693. DOI: 10.1097/WNF.0b013e3181cbf825. View

4.
Kappos L, Radue E, OConnor P, Polman C, Hohlfeld R, Calabresi P . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401. DOI: 10.1056/NEJMoa0909494. View

5.
Cohen J, Barkhof F, Comi G, Hartung H, Khatri B, Montalban X . Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):402-15. DOI: 10.1056/NEJMoa0907839. View